Infliximab and Ulcerative Colitis

Ulcerative colitis (UC) is one of the main forms of inflammatory bowel disease. The condition causes the colon and rectum to become inflamed and ulcerated.

Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study

Pharmaceutics, Free Full-Text

International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease

2021 Pediatric Grand Rounds: “An Update on Pediatric Inflammatory Bowel Disease” (October 29,2021)

Biologic Therapies for Inflammatory Bowel Disease: Strategies for

Antidrug Antibodies to Infliximab and Adalimumab in IBD Management

Infliximab (Remicade) - CredaHealth

Ulcerative colitis - The Lancet

Bad Experience with Remicade (Infliximab) Infusion

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis

JCM, Free Full-Text

PDF) Review Article: Acute Severe Ulcerative Colitis, An Update on Optimal Medical Management

Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial - ScienceDirect